Form 8-K - Current report:
SEC Accession No. 0001104659-24-131957
Filing Date
2024-12-27
Accepted
2024-12-27 08:14:56
Documents
15
Period of Report
2024-12-27
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2431904d1_8k.htm   iXBRL 8-K 24309
2 EXHIBIT 99.1 tm2431904d1_ex99-1.htm EX-99.1 46699
6 GRAPHIC tm24319041d1_ex99-1img001.jpg GRAPHIC 4890
  Complete submission text file 0001104659-24-131957.txt   260323

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA otlk-20241227.xsd EX-101.SCH 3048
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE otlk-20241227_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE otlk-20241227_pre.xml EX-101.PRE 22381
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2431904d1_8k_htm.xml XML 3656
Mailing Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830
Business Address 111 S. WOOD AVENUE UNIT #100 ISELIN NJ 08830 6096193990
Outlook Therapeutics, Inc. (Filer) CIK: 0001649989 (see all company filings)

EIN.: 383982704 | State of Incorp.: DE | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37759 | Film No.: 241582446
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)